Who is Valvanera “Valva” Vozmediano?
-
Valva vozmediano cti is a scientist working in Model-Informed Drug Development and quantitative methods in pharmacology.
-
She currently holds the position of Senior Director of Model Informed Development (MID) at CTI (Clinical Trial & Consulting Services / CTI Laboratories / CTI Group).
-
She is also affiliated with the University of Florida’s Center for Pharmacometrics & Systems Pharmacology (CPSP) as Courtesy Faculty / in an adjunct role.
Education, Career, & Background
-
Education: She earned her B.S. in Pharmacy from the University of the Basque Country (Spain) in 2006, and a Ph.D. in Pharmacology (2011), also from the University of the Basque Country.Postdoctoral & early career: Her doctoral work involved modeling & simulation (M&S) methods. She held a Marie Curie postdoctoral fellowship (B-MOB program) at University of Florida. College of Pharmacy
-
Industry & consulting roles: Before joining CTI, she worked with Dynakin’s Drug Modeling & Consulting group (serving as Principal Consultant and Director of R&D).
-
At CTI: In her role, she leads or guides the application of modeling & simulation, model-informed approaches, regulatory strategies, and consulting in drug development.
Research Focus & Contributions
Valva Vozmediano is recognized for applying quantitative modeling and simulation approaches to drug development and regulatory decision making. Some key themes of her work:
-
Model-Informed Drug Development (MIDD / MID)
She helps integrate modeling & simulation (pharmacometrics, systems pharmacology) to improve decision-making in drug development — e.g. dose selection, bridging studies, pediatric investigations, regulatory interactions. -
Physiologically Based Pharmacokinetic / Pharmacodynamic Modeling (PBPK / PD)
She has co-authored works on applying PBPK in formulation development (e.g. for oral modified release generics) and on absorption processes. -
Regulatory and Translational Modeling
Her work aids regulatory submissions, designing pediatric investigational plans (PIPs), bridging adult-to-pediatric dosing, and addressing regulatory questions with quantitative evidence. -
Application in Clinical Trials & Drug Development Strategy
She supports real trial design and development decisions using modeling simulation, helping reduce risks and improve prediction. -
Publications & Academic Contributions
She has more than 40 peer-reviewed publications and contributes to academic programs, such as being invited professor in the University of the Basque Country and courses at UF.
For example, in a paper titled “Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products”, she is among the authors, highlighting her involvement in mechanistic modeling in formulation development.
Another example is her involvement in dose optimization work using population modeling, such as for carvedilol.
